Sharp Clinical, part of UDG Healthcare and a leading provider of global clinical supply services, has confirmed that it is involved in supporting six clinical trials related to COVID-19.

The company is currently delivering clinical trial packaging, labeling and distribution services for two biotech organizations that are developing potential vaccines for the virus.

Sharp is also delivering a combination of services to support multiple hydroxychloroquine projects, including placebo manufacturing, packaging, labeling, distribution and comparator sourcing, as clinical trials have launched globally to assess the drugs suitability to treat COVID-19 symptoms.

Frank Lis, President of Sharp Clinical said: “We are very proud of the work we do every day in support of our pharma clients, but never more so than today as we actively support our clients’ clinical studies related to COVID-19.

“In the face of this global pandemic, the clinical trials industry continues to focus its attention on the discovery and development of potential vaccines and treatments for COVID-19 and Sharp Clinical is playing its part.

“It is a privilege to be able to contribute to these trials and Sharp will continue to prioritize these COVID-19 projects.  We are doing all we can to protect our own employees in their vital work, so that they can support the industry’s efforts in fighting the disease”.

Sharp's Packaging division also packages and distributes many life-sustaining and life-saving medicines that are needed to maintain peoples' health, including some that treat COVID-19 symptoms, such as high fever.